Exhale 2 & 4 Studies

The EXHALE-2 and EXHALE-4 studies from Areteia Therapeutics will both be testing whether adding a new drug called Dexpramipexole on top of inhaled medications improves the lung function of a person with eosinophilic asthma compared to a placebo administered over 52 weeks (EXHALE-2) or over 24 weeks (EXHALE-4).

The purpose of these studies is to understand more about the safety of Dexpramipexole and how well it works for the treatment of severe eosinophilic asthma.

If you are interested in participating please contact us at research.middlewood@nhs.net